America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy‘.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
How do you envision personalized medicine changing cancer treatment in the future?
**Interview with Dr. Linda Malkas: Pioneering Targeted Chemotherapy**
*Interviewer:* Thank you for joining us today, Dr. Malkas. You and your team at City of Hope Hospital have made significant advances in cancer treatment with your new drug, AOH1996. Can you elaborate on how this drug works?
*Dr. Malkas:* Thank you for having me! AOH1996 is designed to target the cancer variant of a protein known as PCNA, which is crucial for DNA replication and, consequently, tumor growth. Think of PCNA as an airport hub: it facilitates the traffic of proteins necessary for cell division. Our approach acts like a blizzard that disrupts operations at this hub, selectively targeting cancer cells while leaving healthy cells unaffected.
*Interviewer:* That sounds promising. In your research, you tested AOH1996 on over 70 cancer cell lines. What were the key findings of your study?
*Dr. Malkas:* The results were encouraging! AOH1996 was able to selectively kill cancer cells by interrupting their normal reproductive cycles. As a result, we observed a significant reduction in tumor growth in the tested cancer cell lines. This indicates the drug’s potential effectiveness across various cancer types, including breast, prostate, brain, and lung cancers.
*Interviewer:* What are the next steps for AOH1996 following these promising results?
*Dr. Malkas:* The next crucial phase is advancing our findings through clinical trials in humans. We are keen to determine AOH1996’s safety and efficacy in real-world applications. Our goal is to translate this research into an effective treatment that could potentially improve survival rates for cancer patients.
*Interviewer:* This is groundbreaking work! With two decades of research behind you, what are your hopes for the future of targeted chemotherapy?
*Dr. Malkas:* I truly believe that targeted therapies, such as AOH1996, represent the future of cancer treatment. By honing in on the unique characteristics of cancer cells, we can reduce side effects, improve outcomes, and ultimately provide more options for patients. We hope to make significant contributions in the fight against cancer and lead the way to more personalized medicine.
*Interviewer:* Thank you, Dr. Malkas, for sharing your insights. We look forward to seeing the results of your clinical trials and the potential impact on cancer treatment.
*Dr. Malkas:* Thank you! It’s an exciting time for cancer research, and I appreciate the opportunity to discuss our work.